Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Doses of SNS851 Given by Injection in Healthy Adults

What this Trial Is About

Researchers are studying the safety, tolerability, and pharmacokinetics of SNS851, a potent siRNA drug targeting metabolic diseases. This Phase I randomized, double-blind trial involves healthy adult participants aged 18 to 55 years. The study aims to understand how the body handles SNS851 and to observe any side effects when given as single or multiple subcutaneous doses. Participants will be randomly assigned to receive either low to high single or multiple doses of SNS851 or a placebo normal saline. The study is designed to compare these groups while keeping both participants and researchers unaware of group assignments. This method helps to accurately assess the effects of SNS851 without bias. During the study, participants will attend clinic visits to receive doses and be closely monitored for any adverse events. Safety assessments include tracking the incidence and severity of treatment-related side effects up to 3 months after the last dose 6 months for the last multiple-dose group. Participants must complete all study visits and procedures, including physical exams, laboratory tests, and adherence checks, with total participation lasting several months after dosing concludes.

Assess the Safety and Tolerability of SNS851 in Healthy Participants